Clinical Background
Hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) cause 95% of viral hepatitis cases in the U.S.
Epidemiology
- Transmission – variable according to virus
- HAV, hepatitis E (HEV) – fecal-oral
- HBV, HCV, HDV – IV drug abuse, sexual transmission, blood transfusions
Organism
- Diverse group of viruses that share a common ability to cause inflammation and necrosis of the liver
- Virus may persist in a chronic state (HBV, HCV, HDV)
- Patients may remain chronic carriers
- May cause the development of cirrhosis
Risk Factors
- Children in daycare settings (HAV)
- Sexual transmission from HBV- or HCV-positive partner
- HIV-positive patients (HBV, HCV)
- IV drug abusers (HBV, HCV)
- Hemophiliacs (HCV)
- Travel to endemic area (especially Central Asia, Middle East, parts of South America and Africa) (HEV)
Clinical Presentation
- May be difficult to diagnose clinically
- Frequently asymptomatic
- May only have mild rise in aminotransferases (ALT, AST)
- Mild symptoms (malaise, fever, chills, depressed appetite)
- Similar symptoms among viral hepatitis types
- Jaundice is not a predominant symptom in most patients
- Complications – acute liver failure
Treatment
- Acute disease – supportive
- Chronic disease – reduce or eliminate viral loads
Prevention
- Chronic hepatitis is a public health concern for transmission, as well as the development of cirrhosis and hepatocellular carcinoma
- Vaccines are available to immunize against HAV and HBV
Diagnosis
- Indications for testing
- New onset of jaundice, anorexia or dark urine
- Known exposure to hepatitis
- Suspicion of chronic hepatitis (elevated liver enzymes)
- Laboratory testing
- Screen for hepatitis A, B and C infections concurrently, unless specific exposure is known
- Panel testing includes hepatitis B core antibody IgM, hepatitis A IgM, hepatitis C antibody and hepatitis B surface antigen
- HAV antibodies positive indicates acute hepatitis A
- HBV antibodies and surface antigen positive indicate acute hepatitis B or chronic hepatitis
- Repeat surface antigen testing and consider HBV DNA testing
- HCV antibodies positive indicates acute hepatitis C or chronic hepatitis
- High positive should be followed with RNA quantitative testing
- Low positive should be followed with recombinant immunoblot assay (RIBA)
- For further evaluation of hepatitis, refer to specific hepatitis algorithms in ARUP Consult
Differential Diagnosis
- Viral
- Cytomegalovirus (CMV)
- Epstein-Barr virus (EBV)
- Herpes simplex virus (HSV)
- Varicella-zoster virus (VZV)
- Hepatitis A, B, C, D or E
- Toxin exposure
- Nonalcoholic acute steatohepatitis (NASH)
- Drug-induced hepatitis
- Acetaminophen
- Antiseizure medications
- Isoniazid (Nydrazid)
- Oral contraceptives
- Rifampin (Rifadin)
- Sulfonamides
- Autoimmune disease
- Systemic lupus erythematosus (SLE)
- Primary biliary cirrhosis (PBC)
- Sclerosing cholangitis
- Autoimmune hepatitis (AIH)
- Bacterial infection
- Leptospirosis
- Q-fever (Coxiella burnetii)
- Rocky Mountain spotted fever (Rickettsia rickettsii)
- Secondary syphilis (Treponema pallidum)
- Sepsis
- Typhoid fever (Rickettsia typhus)
- Granulomatous
- Mycobacterium tuberculosis (TB)
- Sarcoidosis
- Hereditary
- Wilson disease
- Hemochromatosis
- Alpha-1-antitrypsin deficiency (AAT)
- Ischemic
- Parasitic
- Liver trematodes
- Toxocariasis
Pharmacogenetics and Therapeutic Drug Monitoring
Indications for Laboratory Testing
- Tests generally appear in the order most useful for common clinical situations
- Click on number for test-specific information in the ARUP Laboratory Test Directory
| Test Name and Number |
Recommended Use |
Limitations |
Follow Up |
| Hepatitis Panel, Acute with Reflex to HBsAg Confirmation 0020457 Method: Chemiluminescent Immunoassay/Enzyme Immunoassay |
Confirm infectious agent in patient with acute hepatitis Clarify cause of elevated transaminase levels Panel consists of 4 individual tests: hepatitis A virus antibody, IgM; hepatitis B virus core antibody, IgM; hepatitis B virus surface antigen with reflex to confirmation; hepatitis C virus antibody |
|
|
| Hepatitis C Virus RNA Quantitative, Real-Time PCR 0098268 Method: Real-Time Polymerase Chain Reaction |
Followup test for high positive HCV results |
|
|
| Hepatitis C Virus RNA Quantitative bDNA with Reflex to Hepatitis C Virus Antibody (RIBA), Supplemental 2002683 Method: Branched Chain DNA/Recombinant Immunoblot Assay |
Followup test for low positive HCV results |
|
|
Additional Tests Available
Click the plus sign to expand the table of additional tests.
| Test Name and Number | Comments |
| Hepatitis A Virus Antibody, IgM 0020093 Method: Enzyme Immunoassay |
|
| Hepatitis B Virus Core Antibody, IgM 0020092 Method: Chemiluminescent Immunoassay |
|
| Hepatitis B Virus Surface Antigen with Reflex to Confirmation 0020089 Method: Chemiluminescent Immunoassay |
|
| Hepatitis C Virus Antibody by CIA 2002483 Method: Chemiluminescent Immunoassay |
|
| Hepatitis E Antibody, IgG 0098655 Method: Enzyme-Linked Immunosorbent Assay |
|
| Hepatitis E Antibody, IgM 0098656 Method: Enzyme-Linked Immunosorbent Assay |
|
Guidelines
General References
Comprehensive Review: November 2009
Last Update: November 2009